Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
This study is being done to see if an experimental drug called recombinant interleukin-21
(rIL-21) when given to patients with stage 4 malignant melanoma or stage 4 kidney cancer is
safe and has any effect on these types of cancers.